Glenmark Pharmaceuticals has announced the launch of its version of Spiriva Handihaler tiotropium bromide DPI in Spain, where it will be known as Tavulus. In August 2018, Glenmark announced that it had acquired the rights to market the tiotropium dry powder inhaler in Western Europe.
The company recently launched the tiotropium DPI in the UK, where it is called Tiogiva. According to Glenmark, the inhaler will also be called Tiogiva in Ireland, Sweden, Finland, and Norway; it will be called Tavulus in Denmark and the Netherlands and will be marketed as Tiotropium Glenmark in Germany.
Glenmark VP of Business Development Jiří Havránek commented, “The goal of COPD treatment has always been to provide quick symptomatic relief to patients, and reduce the risk of exacerbations. Since its launch, we have seen the multiple therapeutic benefits of Tavulus in other markets, and we are pleased to extend these benefits to patients in Spain. This inhalation therapy has been shown to significantly aid in the daily management of COPD. We hope that it improves both COPD symptoms and quality of life in those who are most affected.”
Read the Glenmark Pharmaceuticals press release.
